How effective is Cosentyx (secukinumab) for plaque psoriasis?
Cosentyx (secukinumab) is used to treat plaque psoriasis and works by blocking interleukin-17A (IL-17A). In clinical studies, it was able to produce high rates of symptom improvement and skin clearance compared with placebo and active comparators, including improvement measured by PASI-based outcomes (such as PASI 75 and higher thresholds in trials) and reductions in overall disease severity [1][2].
How does Cosentyx compare with other psoriasis biologics (IL-17, IL-23, TNF-α)?
Cosentyx’s key differentiator is that it targets IL-17A. Other biologic classes for psoriasis include:
- IL-23 pathway inhibitors (different targets than IL-17A)
- TNF-α inhibitors (also different mechanisms)
Because these drugs use different endpoints, dosing schedules, and trial designs, direct “head-to-head” comparisons are not always available. What can be compared across evidence is how often patients achieve major skin-clearance milestones (commonly PASI 75/90/100) and how quickly they improve, with Cosentyx generally showing strong clearance rates in its IL-17 A class [1][2].
How quickly does Cosentyx start working, and how fast do skin symptoms improve?
In psoriasis treatment trials, Cosentyx shows improvement early in the course of therapy, and outcomes continue to deepen over subsequent weeks as dosing continues. Skin response is typically assessed using PASI-based measures, and those scores tend to improve over time with ongoing treatment [1][2].
What does “effective” mean in psoriasis trials—what outcomes matter most to patients?
In psoriasis studies, effectiveness is usually described using standardized measures such as:
- PASI-based responses (percent improvement from baseline)
- Investigator Global Assessment (IGA) skin response categories
- Patient-reported improvements in symptoms that track with skin improvement
Cosentyx is evaluated across these types of endpoints in trials and is generally reported as producing high levels of skin improvement in appropriately selected patients [1][2].
Does effectiveness differ by psoriasis severity or by who has tried prior treatments?
Psoriasis patients differ in baseline severity and prior exposure to systemic therapies. In general, biologic effectiveness can vary based on factors such as:
- baseline severity of skin involvement
- prior biologic or non-biologic treatment history
- comorbidities and disease burden
Cosentyx’s trial evidence includes patients across clinically relevant severities and prior-treatment backgrounds, with outcomes reported in standardized response rates (PASI/IGA) [1][2].
Sources
[1] https://www.cosentyx.com/psoriasis
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx